INT113671

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 26
Total Number 26
Disease Relevance 6.33
Pain Relevance 7.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Mmp3) extracellular space (Mmp3) extracellular region (Mmp3)
proteinaceous extracellular matrix (Mmp3) nucleus (Mmp3) protein complex (Mmp3)
Anatomy Link Frequency
neuronal 1
tendon 1
Mmp3 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
metalloproteinase 399 100.00 Very High Very High Very High
antagonist 35 100.00 Very High Very High Very High
nMDA receptor 84 99.50 Very High Very High Very High
Infliximab 6 99.20 Very High Very High Very High
agonist 173 98.52 Very High Very High Very High
pulpitis 2 98.40 Very High Very High Very High
Pain 17 96.00 Very High Very High Very High
Inflammation 37 95.88 Very High Very High Very High
visual analogue scale 2 95.80 Very High Very High Very High
cINOD 5 94.00 High High
Disease Link Frequency Relevance Heat
Tendinopathy 23 99.80 Very High Very High Very High
Pulpitis 2 98.40 Very High Very High Very High
Pain 9 96.00 Very High Very High Very High
INFLAMMATION 41 95.88 Very High Very High Very High
Death 6 95.36 Very High Very High Very High
Adhesions 12 93.52 High High
Apoptosis 9 90.84 High High
Colitis 1 89.36 High High
Cadaver 2 89.04 High High
Cancer 9 87.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The results showed decreased levels of MMP-3, sGAG and TNF-alpha compared with control levels.
Negative_regulation (decreased) of MMP-3
1) Confidence 0.49 Published 2008 Journal Phytother Res Section Abstract Doc Link 17726731 Disease Relevance 0.44 Pain Relevance 0.25
Interestingly, inhibition of MMP-3 and MMP-9 was shown recently to effect spatial learning and synaptic plasticity in rats [25].
Negative_regulation (inhibition) of MMP-3
2) Confidence 0.49 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2443283 Disease Relevance 0.11 Pain Relevance 0.15
suggest a link between inhibition of hippocampal MMP-3 and -9 and
Negative_regulation (inhibition) of MMP-3 associated with metalloproteinase
3) Confidence 0.41 Published 2007 Journal Neural Plasticity Section Body Doc Link PMC1838960 Disease Relevance 0 Pain Relevance 0.47
The capacity of pilocarpine to prevent iNOS activity, PGE(2), and MMP-3 by acting on mAChR mutation induced by pulpitis might be useful therapeutically as a local treatment.
Negative_regulation (prevent) of MMP-3 associated with pulpitis
4) Confidence 0.32 Published 2009 Journal J Endod Section Abstract Doc Link 19345799 Disease Relevance 0.37 Pain Relevance 0.32
We propose a model in which MMP-3 may be activated under conditions of strong NMDA receptor stimulation in vivo and MMP-3-mediated NR1 subunit inactivation by ectodomain shedding may antagonize the over-stimulation of the NMDA receptors in order to prevent neuronal cell death.
Negative_regulation (inactivation) of MMP-3-mediated in neuronal associated with nmda receptor and death
5) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2443283 Disease Relevance 0.61 Pain Relevance 0.21
Inhibition of Hippocampal Matrix Metalloproteinase-3 and -9
Negative_regulation (Inhibition) of Matrix Metalloproteinase-3 associated with metalloproteinase
6) Confidence 0.30 Published 2007 Journal Neural Plasticity Section Title Doc Link PMC1838960 Disease Relevance 0.09 Pain Relevance 0.50
Infusions of infliximab in AS patients led to a significant decrease in the values of the BASDAI as well as the serum MMP-3, but no change in the serum M-CSF values.
Negative_regulation (decrease) of MMP-3
7) Confidence 0.25 Published 2004 Journal Arthritis Rheum. Section Body Doc Link 15478146 Disease Relevance 0.08 Pain Relevance 0
The reduction of serum MMP-3 was positively correlated to decrement of ESR and CRP (r=0.397 and 0.474, respectively, P<0.05).
Negative_regulation (reduction) of serum MMP-3
8) Confidence 0.21 Published 2008 Journal Nan Fang Yi Ke Da Xue Xue Bao Section Body Doc Link 18753057 Disease Relevance 0 Pain Relevance 0
Etanercept treatment resulted in a significant reduction in serum MMP-3 level in the AS patients to 31.22-/+10.26 ng/ml as compared with the level before treatment (46.17-/+25.74 ng/ml, P<0.05).
Negative_regulation (reduction) of serum MMP-3
9) Confidence 0.21 Published 2008 Journal Nan Fang Yi Ke Da Xue Xue Bao Section Body Doc Link 18753057 Disease Relevance 0 Pain Relevance 0
Although infliximab infusions led to rapid and significant suppression of serum MMP-3 levels, serum MMP-3 levels did not distinguish responders from non-responders.
Negative_regulation (suppression) of MMP-3 associated with infliximab
10) Confidence 0.20 Published 2008 Journal Clin. Rheumatol. Section Abstract Doc Link 18566849 Disease Relevance 0.14 Pain Relevance 0.44
At 12 and 24 weeks, significant reductions in urinary CTX-II and MMP-3, but not NTX concentrations, were observed for adalimumab versus placebo (p<0.001).
Negative_regulation (reductions) of MMP-3
11) Confidence 0.19 Published 2008 Journal J. Rheumatol. Section Body Doc Link 18785308 Disease Relevance 0.07 Pain Relevance 0
In their rabbit flexor tendon model, Asundi and Rempel described MMP 3, but not MMP 1 inhibition [25].
Negative_regulation (inhibition) of MMP 3 in tendon associated with metalloproteinase
12) Confidence 0.18 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2998463 Disease Relevance 0.25 Pain Relevance 0.58
CONCLUSION: Infliximab and Etanercept, 2 anti-TNF-alpha inhibitors, not only significantly decrease the ESR and CRP, but also decrease the serum level of MMP-3 of patients with AS.
Negative_regulation (decrease) of MMP-3
13) Confidence 0.18 Published 2006 Journal Zhonghua Yi Xue Za Zhi Section Body Doc Link 17156669 Disease Relevance 0 Pain Relevance 0
ESR and CRP levels did not change, but serum MMP-3 levels decreased in the glucosamine group.
Negative_regulation (decreased) of MMP-3
14) Confidence 0.11 Published 2007 Journal Rheumatol. Int. Section Abstract Doc Link 16953394 Disease Relevance 0.33 Pain Relevance 0.30
Serum levels of TGF-Beta, MMP-3, and M-CSF were significantly decreased after 12 weeks of treatment (p < 0.05).
Negative_regulation (decreased) of MMP-3
15) Confidence 0.11 Published 2007 Journal J. Rheumatol. Section Body Doc Link 17610317 Disease Relevance 0.06 Pain Relevance 0
Dexamethasone, IL-1-Ra and TNF inhibitor decreased active MMP-3, indicating that the clinical use of these drugs may affect the resorption of DH under certain conditions.


Negative_regulation (decreased) of MMP-3
16) Confidence 0.09 Published 2009 Journal Arthritis Res. Ther. Section Body Doc Link 19906289 Disease Relevance 0 Pain Relevance 0
Consistently, the levels of mRNA for MMP-3 and -13 were reduced by 50% and by 10%, respectively, whereas those for TIMP-1 were upregulated by 65% (Table 2).
Negative_regulation (reduced) of MMP-3 associated with metalloproteinase
17) Confidence 0.09 Published 2010 Journal PPAR Research Section Body Doc Link PMC2957135 Disease Relevance 0 Pain Relevance 0.68
In contrast, it decreased global MMP or specific MMP-13 activities, while decreasing MMP-3 or MMP-13 mRNA levels.
Negative_regulation (decreasing) of MMP-3 associated with metalloproteinase
18) Confidence 0.09 Published 2010 Journal PPAR Research Section Abstract Doc Link PMC2957135 Disease Relevance 0 Pain Relevance 0.68
Wy14643 was solely associated with inhibition of basal MMP-3 & -13 mRNA expression and basal global MMP (-1, -2, -3, -7, and -9) or specific MMP-13 activities whereas all PPAR agonists reduced the stimulatory effect of TGF-?
Negative_regulation (inhibition) of MMP-3 associated with agonist and metalloproteinase
19) Confidence 0.07 Published 2010 Journal PPAR Research Section Body Doc Link PMC2957135 Disease Relevance 0.76 Pain Relevance 0.59
In addition, the effects on matrix metalloproteinase MMP-3 and its antagonist tissue inhibitor of matrix-metalloproteinase 3 (TIMP-1) were determined.
Negative_regulation (inhibitor) of matrix-metalloproteinase 3 associated with antagonist and metalloproteinase
20) Confidence 0.07 Published 2007 Journal Curr Med Res Opin Section Abstract Doc Link 17631696 Disease Relevance 0.56 Pain Relevance 0.64

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox